Frances Stocks Allen

Cooley advised Ochre Bio, a UK-based pioneer in chronic liver disease medicine development with labs in New York and Taipei, on its partnership with Boehringer Ingelheim focused on the discovery and development of novel, first-in-class regenerative treatments for chronic liver diseases, such as late-stage metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis.

Cooley advised Quell Therapeutics, a leading T-regulatory (Treg) cell therapy biotech company based in London, on its exclusive collaboration with AstraZeneca.